Arcutis Biotherapeutics price to sales ratio ARQT

Market value divided by revenue over the last twelve months, since 2023.

Today, Oct 23, 2026: 8.5×
3-year median: 8.9×
Against its 3-year history: 45th; percentile: 0 is its lowest day, 100 its highest
3-year range: 3.7× to 47.4×
Peer median: 3.5×

Arcutis Biotherapeutics' price to sales ratio is 8.5× as of Oct 23, 2026.

That is below its 3-year median of 8.9×, close to the middle of its last 3 years.

Over that time it ranged from 3.7× in Nov 2023 to 47.4× in Aug 2023.

The median for 10 large drugmakers of a similar size is 3.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.5×	6.3×	11.2×
2025	11.2×	6.7×	12.3×
2024	12.1×	6.3×	19.1×
2023	6.2×	3.7×	47.4×

Against its peers

Companies in Drug Manufacturers - General nearest Arcutis Biotherapeutics' size, closest first, today.

Company	Price to sales ratio
ARQTArcutis Biotherapeutics	8.5×
LQDALiquidia	8.5×
INDVIndivior Pharmaceuticals	3.1×
OGNOrganon	0.6×
NRIXNurix Therapeutics	3.9×
KNSAKiniksa Pharmaceuticals International	7.1×
LGNDLigand Pharmaceuticals	20.8×
AMRXAmneal Pharmaceuticals	2.1×
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
ALKSAlkermes plc.	4.4×
Peer median	3.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Arcutis Biotherapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.